Title: Implementing Expanded Seasonal Influenza Vaccination: Federal Perspective
1Implementing Expanded Seasonal Influenza
Vaccination Federal Perspective
- Jeanne M. Santoli (jsantoli_at_cdc.gov)
- Immunization Services Division
- National Center for Immunization and Respiratory
Diseases - July 14, 2008
2Outline
- Vaccine supply
- Vaccine financing
- Vaccine coverage
- Vaccine safety monitoring
- Public health infrastructure
- Supporting activities
- New knowledge
- CDCs annual campaign
3Approved Influenza Vaccines and Supply
Projections, United States 2008-09 Season
Vaccine Trade name Manufacturer Presentation Age group Projected Production (Doses)
TIV Fluzone sanofi pasteur .25 mL prefilled syringe 0.5 mL prefilled syringe 0.5 mL vial 5.0 mL multi-dose vial 6-35 mo gt 36 mo gt 36 mo gt 6 mo 50 m
TIV Afluria CSL 5.0 multi-dose vial 0.5 mL prefilled syringe gt 18 years 6 m
TIV Fluvirin Novartis Vaccine 5.0 mL multi-dose vial 0.5 mL prefilled syringe gt 4 years 40 m
TIV Fluarix Glaxo SmithKline 0.5 mL prefilled syringe gt 18 years 35-38 m 1/3 Fluarix, 2/3 Flulaval
TIV Fluluval Glaxo SmithKline 5.0 mL multi-dose vial gt 18 years 35-38 m 1/3 Fluarix, 2/3 Flulaval
LAIV FluMist MedImmune 0.2 mL sprayer 2-49 years 12 m
Total Projected Production Total Projected Production Total Projected Production Total Projected Production Total Projected Production 143-146 m
As reported May 12, 2008 at the National
Influenza Vaccine Summit, Atlanta, GA.
4Influenza Vaccine Production and Distribution,
US, 1980-2007
Doses Produced (millions) Dose Distributed (millions) Difference (millions)
1980 15.7 12.4 3.3
1990 32.3 28.3 4.0
1995 71.5 54.9 16.6
1999 77.2 76.8 0.5
2000 77.9 70.4 7.5
2001 87.7 77.7 10.0
2002 95.0 83.0 12.0
2003 86.9 83.1 3.8
2004 61.0 57.0 4.0
2005 86.0 81.2 7.0
2006 120.9 102.5 18.4
2007 140.6 112.8 27.8
5Influenza Vaccine Production and Distribution,
US, 1980-2007
6Sufficiency of Supply
- 27 million doses of vaccine were not
distributed in 07-08 - A mismatch between supply and demand not
surprising when both supply and recommendations
are changing - There have been steady increases in doses
distributed over past several years - 81 million doses (2005-06)
- 103 million doses (2006-07)
- 113 million doses (2007-08)
- Given projected production for upcoming season
and data about uptake of new vaccine
recommendations, including uptake of recent
expanded flu recommendations, we anticipate that
supply will likely be sufficient to meet demand
7Production Projections for Thimerosal-free or
Preservative-free Influenza Vaccines, United
States
2007-08 Season 2008-09 Season
Doses licensed for use in children 6-35 months of age 12 m 20 m
Total doses 30 m 50 m
Represents production capacity for products as
reported by the influenza vaccine manufacturers
prior to the 2007-08 season. Represents
production capacity, as reported on May 12, 2008
by influenza vaccine manufacturers at the
National Influenza Vaccine Summit in Atlanta, GA.
NOTE Translation of capacity into actual
production depends upon production yields, lot
release, and demand for product.
8Financing for Flu Vaccine
- VFC resolution adopted Feb 2008 to cover expanded
recommendations - Vaccine available on CDC contracts has increased
steadily - Approximately 12.5 million doses across all
products in 08-09 - Issue of low administration fees for VFC impacts
influenza vaccination as well as other routine
vaccines - Section 317 Report calls for increased funding
for underinsured children and adolescents to
cover routine vaccines, including influenza - Private insurance coverage for flu vaccine
- Time lag for new vaccines vs. expanded recs?
9Influenza Vaccination Coverage Among Children
6-23 Months of Age, National Immunization Survey,
2002-2006
Vaccinate all 6-23 month olds recommendation
Encourage vaccination of 6-23 month olds
10How do we measure seasonal flu coverage in
children?
- National Immunization Survey
- Provider-verified
- Routinely assesses
- Children 19-35 months (state level)
- Children 13-17 years (state level beginning 08)
- National Health Interview Survey
- All ages, national data, self reported
- BRFSS
- Self reported
- Child flu vaccination module available in 2006
- Immunization Information Systems
- Provider verified
- Small area/practice level estimates possible
- Status of IIS varies by region
11Vaccine Safety Monitoring
- ACIP Influenza Working Group reviewed available
vaccine safety data as part of deliberation
process - Available data suggest widespread use of TIV/LAIV
would be safe - Existing systems are in place for initial safety
monitoring - Additional efforts needed to optimize safety
monitoring in non-traditional or non-healthcare
settings
12Public Health Infrastructure for Influenza
Vaccine Delivery
- Broad interest in use of venues that are
unrelated to vaccination or healthcare to capture
school-aged children - In contrast to traditional or non-traditional
medical settings, these venues will require staff
to deliver vaccines - Delivery will likely either be public health
staff or overseen by public health staff - Current public health infrastructure is likely
insufficient to play these roles across the US
13A Second Public Health Infrastructure Issue
- Use of non-traditional and/or non-healthcare
venues increases need for information- sharing to
preserve continuity of care - Immunization information system (IIS) development
in the US continues, traditional focus has been
on younger children - In 2006, 65 of children lt 6 yrs participated in
an IIS - 84 of grantees report maintaining vaccination
data in IIS for persons 11-18 yrs
IIS ProgressUS, 2006, MMWR March 21, 2008
Vol57/N0 11, pp 289-91.
14New Knowledge
- Two RFAs focused on school-based vaccination were
posted by CDC this year - One RFA focuses specifically on influenza
vaccination - Goal was to identify sustainable projectsso
involvement of billing entity was required - RFAs targeted toward state and local health
departments - Another RFA focuses on strategies for private
providers to use a longer vaccination season to
vaccinate their patients
15Promotion of the Expanded Seasonal Recommendations
- CDCs traditional seasonal campaign enhanced with
new materials for providers and public - Highlight benefits of decreased school
absenteeism, more time for learning - Routine childhood and pre-teen/adolescent
materials updated to include influenza
recommendations for these children - NIVW to be sponsored December 8-14, 2008 more
information is available at http//www.cdc.gov/f
lu/NIVW/NIVW2008-index.htm - Collaboration with Families Fighting Flu to
sponsor Childrens Vaccination Day during NIVW
16Summing Up
- Manufacturers project a large supply of vaccine
for 08-09 season - Vaccine financing issues similar to other
childhood vaccines - Underinsured children/adolescents are the primary
gap - Vaccine coverage is low in young children
- Enhancements to current systems for monitoring
vaccine coverage and safety are needed as current
mechanisms are not optimized to the newly added
agegroup and potential new venues - Increased public health infrastructure is needed
to support implementation of expanded
recommendations - Knowledge gaps around immunization delivery exist
and efforts are being made to fill them
17Acknowledgments
- Karen Broder
- Gary Euler
- John Iskander
- Lance Rodewald
- Tammy Santibanez
- Kris Sheedy
- Abigail Shefer
- Greg Wallace
- Karen Wooten